A Safety and Efficacy Study of BLI-1300 Ointment in Symptomatic Perianal Crohn's Disease

Trial Profile

A Safety and Efficacy Study of BLI-1300 Ointment in Symptomatic Perianal Crohn's Disease

Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 Feb 2015

At a glance

  • Drugs Metronidazole (Primary)
  • Indications Bacterial infections; Crohn's disease; Pain
  • Focus Therapeutic Use
  • Sponsors Braintree Laboratories
  • Most Recent Events

    • 25 Oct 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 27 Sep 2012 New source identified and integrated (Vanderbilt University Medical Center).
    • 28 Jul 2012 New source identified and integrated (Mayo Clinic).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top